Adverse Events Following Immunization of mRNA and Inactivated Vaccines Against COVID-19 at Universitas Indonesia Hospital: A Cross-Sectional Study
DOI:
https://doi.org/10.36497/jri.v43i2.429Keywords:
AEFI, COVID-19, Pfizer, Sinovac, vaccineAbstract
Background: The coronavirus that causes severe acute respiratory syndrome (COVID-19) is coronavirus 2 (SARS-CoV- 2). This virus has caused a global pandemic. The adverse impact of this virus in the past two years has resulted in efforts to build herd immunity through vaccination. This study aimed to identify the side effects after getting the Pfizer and Sinovac vaccines at the Universitas Indonesia Hospital and the risk factors for Adverse Events Following Immunization (AEFI).
Methods: This observational study used a descriptive, non-experimental method with a cross-sectional design. Google Forms was used to collect data.
Results: The onset of AEFI symptoms ranged from 15 minutes to 24 hours. The common AEFI symptoms were pain at the injection site, fatigue, muscle aches, and joint pain. The AEFI severity was mostly at the mild level, and only a few participants took medication. Female participants, participants with comorbidities and allergies, previous medication histories within the last 6 months, and those with experience of COVID-19 had a higher risk for AEFI with a statistically significant effect (P <0.005).
Conclusion: This study revealed that Pfizer and Sinovac COVID-19 vaccines were safe to administer as the AEFIs were mostly mild and automatically disappeared and decreased after 1 to 3 days.
Downloads
References
Long B, Carius BM, Chavez S, Liang SY, Brady WJ, Koyfman A, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. American Journal of Emergency Medicine. 2022;54:46–57.
Djalante R, Lassa J, Setiamarga D, Sudjatma A, Indrawan M. Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020. Prog Disaster Sci. 2020;6:100091.
Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, et al. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Front Immunol. 2022;12:1–21.
Selvaraj P, Muthu S, Jeyaraman N. Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India. Clin Epidemiol Glob Health. 2022;14:100983.
Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):1–16.
Sukamto Koesnoe. Teknis Pelaksanaan Vaksin Covid dan Antisipasi KIPI. Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia. 2021;1–65.
Mohsin M, Mahmud S, Uddin Mian A, Hasan P, Muyeed A, Taif Ali M, et al. Side effects of COVID-19 vaccines and perceptions about COVID-19 and its vaccines in Bangladesh: A Cross-sectional study. Vaccine X. 2022;12:100207.
Lai FTT, Leung MTY, Chan EWW, Huang L, Lau LKW, Peng K, et al. Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring. Vaccine. 2022;40(10):1390–6.
Bostan E, Yel B, Karaduman A. Cutaneous adverse events following 771 doses of the inactivated and mRNA COVID-19 vaccines: A survey study among health care providers. J Cosmet Dermatol. 2022;21(9):3682–8.
Aryal S, Devbhandari RP, Shrestha S, Shrestha A, Rajbhandari P, Shakya T, et al. Adverse events following Sinopharm (Vero Cell), the inactivated COVID-19. Journal of Patan Academy of Health Sciences. 2021;8(2):18–24.
Anjorin AA, Odetokun IA, Nyandwi JB, Elnadi H, Awiagah KS, Eyedo J, et al. Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa. MDPI Vaccines. 2022;10:1–18.
Le XTT, Hoang QL, Ta NTK, Pham QT, Nguyen TT, Phan HTM, et al. Common adverse events following immunization with the COVID-19 comirnaty vaccine (Pfizer-BioNTech) among adult population in Hanoi, Vietnam, 2021. Frontiers in Tropical Diseases. 2022;3(September):1–9.
Parida SP, Sahu DP, Singh AK, Alekhya G, Subba SH, Mishra A, et al. Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol. 2022;94(6):2453–9.
Ripabelli G, Tamburro M, Buccieri N, Adesso C, Caggiano V, Cannizzaro F, et al. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. J Community Health. 2022;47(2):211–25.
Chakraborty A, Reval N, Kamath L. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India. Cureus. 2022;14(2):1–9.
Hidayat R, Mustika AP, Avisha F, Djuliannisaa Z, Winari DD, Putri RA, et al. Surveillance of Adverse Events Following Immunization ( AEFI ) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel. MDPI Vaccines. 2022;10:1–10.
Iguacel I, Maldonado AL, Ruiz-Cabello AL, Casaus M, Moreno LA, Martínez-Jarreta B. Association between covid-19 vaccine side effects and body mass index in Spain. Vaccines (Basel). 2021;9(11):1–12.
Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 2021;10(1):94.
Juliane Z, Adisasmita AC, Yuniadi Y. Risk Factors for Mortality of Patients with COVID-19 in RSJPD Harapan Kita, Jakarta Zhara. J Respir Indo. 2022;42.
Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: A post-marketing Italian study conducted between 1 January and 28 February 2021. European Journal of Hospital Pharmacy. 2021;1–6.
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7).
Maruyama A, Sawa T, Teramukai S, Katoh N. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers. Journal of Infection and Chemotherapy. 2022;28(7):934–42.
Downloads
Additional Files
- Supplementary Data
- Turnitin
- PUBLISHING AGREEMENT
- Main doc - Adverse Events Following Immunization of mRNA And Inactivated Vaccines Against Covıd-19 at The University of Indonesia Hospital: A Cross-Sectional Study
- Main doc - Adverse Events Following Immunization of mRNA And Inactivated Vaccines Against Covıd-19 at The University of Indonesia Hospital: A Cross-Sectional Study
- Rev- Main document
- Revisi - Supplementary Data
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
